Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO Breast 2020 | HR+ breast cancer: endocrine therapy, surgery and radiotherapy

Michael Gnant, MD, Vienna General Hospital, Vienna, Austria, discusses the 10-year results of the Austrian breast and colorectal cancer study group 8A trial results of patients with hormonal receptor-positive (HR+) breast cancer treated with breast-conserving surgery and consecutive endocrine therapy with or without whole breast irradiation. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).